Clinical Outcomes After EMR or ESD of Colorectal Neoplasms - A Multicenter Registry
Status
Conditions
Treatments
Details and patient eligibility
About
This study aims to establish a multicenter registry platform to capture clinical data from subjects undergoing colorectal EMR and ESD.
Full description
Colorectal cancer (CRC) is one of the most common causes of cancer-related death, however its morbidity and mortality can be reduced by colonoscopy screening and endoscopic removal of adenomas or early cancers.[1] Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are two main endoscopic treatment options for colorectal neoplasms. Despite being a safe and convenient procedure, insufficient resection by EMR can result in a high risk of local recurrence, particularly in lesions ≥ 20 mm. Compared with EMR, ESD facilitates a higher rate of en bloc resection and a lower rate of local recurrence. A recent meta-analysis revealed that the local recurrence rate after colorectal ESD was 1% during a 2-year follow-up period. In addition, ESD can facilitate precise pathological diagnosis to assess the risk of lymph node metastasis of early CRC to judge whether salvage surgery is needed. Although the efficacy of colorectal ESD has been demonstrated, its usage is largely limited by its technical difficulty and risk of complications.
Both short- and long-term data on clinical outcomes and safety profiles for colorectal EMR and ESD are needed. Therefore, this study aims to establish a multicenter registry platform to capture clinical data from subjects undergoing colorectal EMR and ESD.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Subjects who undergo EMR or ESD for colorectal lesions.
Exclusion criteria
- Not applicable.
Trial design
2,500 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Louis Lau
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal